tetano
Editor, Senior Moderator
Case Rep Neurol Med
. 2023 May 27;2023:7061783.
doi: 10.1155/2023/7061783. eCollection 2023. Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy following mRNA SARS-CoV-2 Vaccination
Marta Rodrigues de Carvalho[SUP] 1 [/SUP], Myrian Mathildes Sá de Deus Rocha[SUP] 1 [/SUP], Vinícius Alves Bezerra[SUP] 2 [/SUP], Maciel Eduardo de Pontes[SUP] 1 [/SUP], Maria Cristina Del Negro[SUP] 3 [/SUP], Julio Salgado Antunes[SUP] 4 [/SUP], Vinícius Viana Abreu Montanaro[SUP] 3 [/SUP], Rubens Nelson Morato Fernandez[SUP] 1 [/SUP]
Affiliations
The new coronavirus (COVID-19) pandemic has resulted in the unprecedented production of vaccines. In this context, the possible adverse effects remain to be identified and reported. In this article, we report the case of a young female patient who developed anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMG-CoA) immune-mediated necrotizing myositis (IMNM) after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine. The diagnosis of probable post-vaccination IMNM was made due to the absence of other factors that may have led to the development of autoantibodies (medicines; e.g., statins, drugs) and the temporal relationship between exposure and event. This case report is the first to suggest that a COVID-19 vaccine may trigger anti-HMG-CoA reductase necrotizing myopathy.
. 2023 May 27;2023:7061783.
doi: 10.1155/2023/7061783. eCollection 2023. Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy following mRNA SARS-CoV-2 Vaccination
Marta Rodrigues de Carvalho[SUP] 1 [/SUP], Myrian Mathildes Sá de Deus Rocha[SUP] 1 [/SUP], Vinícius Alves Bezerra[SUP] 2 [/SUP], Maciel Eduardo de Pontes[SUP] 1 [/SUP], Maria Cristina Del Negro[SUP] 3 [/SUP], Julio Salgado Antunes[SUP] 4 [/SUP], Vinícius Viana Abreu Montanaro[SUP] 3 [/SUP], Rubens Nelson Morato Fernandez[SUP] 1 [/SUP]
Affiliations
- PMID: 37275628
- PMCID: PMC10239300
- DOI: 10.1155/2023/7061783
The new coronavirus (COVID-19) pandemic has resulted in the unprecedented production of vaccines. In this context, the possible adverse effects remain to be identified and reported. In this article, we report the case of a young female patient who developed anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMG-CoA) immune-mediated necrotizing myositis (IMNM) after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine. The diagnosis of probable post-vaccination IMNM was made due to the absence of other factors that may have led to the development of autoantibodies (medicines; e.g., statins, drugs) and the temporal relationship between exposure and event. This case report is the first to suggest that a COVID-19 vaccine may trigger anti-HMG-CoA reductase necrotizing myopathy.